Glioblastoma multiforme

Current Treatment Options in Neurology

Volumn 10, Issue 4, 2008, Pages 285-294

  Newton, Herbert B ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; KETOCONAZOLE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PHENYTOIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RETINOIC ACID; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VALPROIC ACID; VATALANIB;

ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; AUTONOMIC DYSFUNCTION; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHOLINERGIC SYMPTOM; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; CRANIOTOMY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FLUID RETENTION; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG EDEMA; MOLECULAR THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NEUROSURGERY; PERIPHERAL EDEMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 58649089546     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0031-z     Document Type: Review

References (68)

1. Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Miller CR, Perry A: Glioblastoma. Morphologic and molecular genetic diversity. Arch Pathol Lab Med 2007, 131:397-406.
3. Newton HB, Malkin MG: Overview of brain tumor epidemiology. In Handbook of Neuro-Oncology Neuroimaging. Edited by Newton HB, Jolesz FA. Amsterdam: Elsevier/Academic Press; 2007: 341-354.
4. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
5. Mirimanoff R, Mason W, Van den Bent M, et al.: Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC phase III randomized trial on radiotherapy (RT) and concomitant adjuvant temozolomide (TMZ) versus RT alone [abstract]. Int J Radiat Oncol Biol Phys 2007, 69:S2.
6. Cavaliere R, Wen PY, Schiff D: Novel therapies for malignant gliomas. Neurol Clin 2007, 25:1041-1071.
7. Chinot OL, Barrié M, Fuentes S, et al.: Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007, 25:1470-1475.
8. Newton HB, Dalton J, Figg G, et al.: Long-term therapy of brain tumors with temozolomide: Review of tolerability and efficacy in 47 patients [abstract]. Neuro Oncol 2007, 9:522-523.
9. Chamberlain MC, Chalmers L: A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol 2007, 82:207-209.
10. Groves MD, Puduvalli VK, Chang SM, et al.: A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007, 81:271-277.
11. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003. l outcome.
12. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al.: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
13. Hegi ME, Diserens AC, Godard S, et al.: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
14. Crinière E, Kaloshi G, Laigle-Donadey F, et al.: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007, 83:173-179.
15. Mischel PS, Cloughesy TF: Targeted molecular therapy of glioblastoma. Brain Pathol 2004, 13:52-61.
16. Newton HB: Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther 2003, 3:595-614.
17. Newton HB: Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004, 4:105-128.
18. Newton HB: Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 5 - apoptosis and cell cycle. Expert Rev Anticancer Ther 2005, 5:355-378.
19. Sathornsumetee S, Reardon DA, Desjardins A, et al.: Molecularly targeted therapy for malignant gliomas. Cancer 2007, 110:13-24.
20. Newton HB: Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Curr Opin Investig Drugs 2007, 8:1009-1021.
21. Viola FS, Katz A, Arantes A, et al.: Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):89s.
22. Dresemann G, Hosius C, Nikolova Z, Letvak L: Single center phase II trial analyzing the role of imatinib/hydroxyurea in patients with pretreated non-progressive glioblastoma (GBM) as maintenance treatment [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):88s.
23. Dresemann G, Rosenthal M, Höffken K, et al.: Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) - an international open label randomized phase III study (Ambrosia-Study) [abstract]. Neuro Oncol 2007, 9:519.
24. Sathornsumetee S, Rich JN, Vredenburgh JJ, et al.: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):81s.
25. Franceschi E, Cavallo G, Lonardi S, et al.: Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007, 96:1047-1051.
26. Van Den Bent MJ, Brandes AA, Rampling R, et al.: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 [abstract]. Neuro Oncol 2007, 9:522.
27. DeGroot JF, Gilbert MR, Hess KR, et al.: Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):81s.
28. Robins HI, Wen PY, Chang SM, et al.: Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 0402) [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):89s.
29. Prados M, DeBoer R, Chang S, et al.: Phase II study of tarceva plus temodar during and following radiotherapy in patients newly diagnosed with glioblastoma or gliosarcoma [abstract]. Neuro Oncol 2007, 9:528.
30. Lassman A, Holland E, DeAngelis L, et al.: Clinical and molecular-metabolic phase II trial of perifosine for recurrent/ progressive malignant glioma [abstract]. Neuro Oncol 2007, 9:518-519.
31. Sartore-Bianchi A, Ricotta R, Cerea G, et al.: Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers 2007, 22(Suppl 4):S77-S87.
32. Wilhelm S, Carter C, Lynch M, et al.: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nature Rev Drug Discov 2007, 5:835-844.
33. Nabors LB, Rosenfeld M, Chamberlain M, et al.: A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401) [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):89s.
34. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
35. Cavallaro U, Christofori G: Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000, 50:63-70.
36. Webb CP, Vande Woude GF: Genes that regulate metastasis and angiogenesis. J Neurooncol 2000, 50:71-87.
37. Plate KH: Mechanisms of angiogenesis in the brain [review]. J Neuropath Exp Neurol 1999, 58:313-320.
38. Jensen RL: Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review. Surg Neurol 1998, 49:189-196.
39. Dunn IF, Heese O, Black PM: Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000, 50:121-137.
40. Zagzag D, Zhong H, Scalzitti JM, et al.: Expression of hypoxia-inducible factor 1α in brain tumors. Association with angiogenesis, invasion, and progression. Cancer 2000, 88:2606-2618.
41. Jiang BH, Jiang G, Zheng JZ, et al.: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001, 12:363-369.
42. Wen S, Stolarov J, Myers MP, et al.: PTEN controls tumorinduced angiogenesis. Proc Natl Acad Sci U S A 2001, 98:4622-4627.
43. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
44. Levine AM, Tulpule A, Quinn DI, et al.: Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006, 24:1712-1719.
45. Wachsberger PR, Burd R, Cardi C, et al.: VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007, 67:1526-1537.
46. Ranieri G, Patruno R, Ruggieri E, et al.: Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 2006, 13:1845-1857.
47. Shih T,ALindley C: Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Therap 2006, 28:1779-1802.
48. Kunkel P, Ulbricht U, Bohlen P, et al.: Inhibition of intracranial glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
49. Stefanik DF, Fellows WK, Rizkalla LR, et al.: Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 2001, 55:91-100.
50. Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract 342]. Neuro Oncol 2005, 7:369.
51. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
52. Goli KJ, Desjardins A, Herndon JE, et al.: Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):75s.
53. Vredenburgh JJ, Desjardins A, Herndon JE, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
54. Kang T, Jin T, Peereboom D: Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):94s.
55. Raval S, Hwang S, Dorsett L: Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):94s.
56. Hasselbalch B, Lassen U, Grunnet K, et al.: Bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), and irinotecan for treatment of recurrent primary malignant brain tumors in adults. Neuro Oncol 2007, 9:514.
57. Raizer JJ, Gallot L, Cohn R, et al.: A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):94s.
58. Pope WB, Lai A, Nghiemphu P, et al.: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260.
59. Chen W, Delaloye S, Silverman DHS, et al.: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007, 25:4714-4721.
60. Gordon MS, Cunningham D: Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69(Suppl 3):25-33.
61. Goldbrunner RH, Bendszus M, Wood J, et al.: PTK787/ZK2222584, an inhibitor of vascular endothelial growth factor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004, 55:426-432.
62. ScottTEN, Meinhardt G, Jacques C, et al.: Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 2007, 16:367-379.
63. Brandes AA, Stupp R, Hau P, et al.: EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma-results of a phase I trial [abstract 2026]. J Clin Oncol 2007, 25(June 20 Suppl):81s.
64. WedAe SR, Kendrew J, Hennequin LE, et al.: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
65. Batchelor TT, Sorensen AG, de Tomaso E, et al.: AZD2171, a pan VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
66. Batchelor T, Sorensen AG, Ancukiewicz M, et al.: A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma [abstract]. J Clin Oncol 2007, 25(June 20 Suppl):75s.
67. Asthagiri AR, Pouratian N, Sherman J, et al.: Advances in brain tumor surgery. Neurol Clin 2007, 25:975-1003.
68. Stieber VW, Mehta MP: Advances in radiation therapy for brain tumors. Neurol Clin 2007, 25:1005-1033.